BioNTech and BMS’ Pumitamig Shows Promise in Phase II TNBC Trial

BioNTech and Bristol Myers Squibb’s PD-1×VEGF bispecific antibody pumitamig has demonstrated encouraging efficacy and safety in a Phase II trial for frontline and second-line triple-negative breast cancer (TNBC). If approved, pumitamig could become the first bispecific antibody authorised for TNBC.

In the ongoing Phase II study, 39 evaluable patients treated with pumitamig plus chemotherapy agent Abraxane achieved a nine-month progression-free survival rate of 59.3%. The confirmed objective response rate reached 61.5%, while disease control was observed in over 92% of patients. Responses appeared independent of PD-L1 expression and prior treatment history, with higher doses linked to stronger anti-tumour activity.

The combination therapy was generally well tolerated. Grade 3 or higher treatment-emergent adverse events occurred in about 43% of patients, with no treatment-related deaths reported. The findings were presented at the 2025 San Antonio Breast Cancer Symposium, highlighting growing interest in PD-1×VEGF bispecific strategies within immuno-oncology.

18-12-2025